Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-07-15
    E.g., 2018-07-15

Articles

Pages

172820 items
1:07 PM, Jul 13, 2018  |  BC Week In Review | Company News  |  Other News

Regulus reducing headcount by 60%

Regulus Therapeutics Inc. (NASDAQ:RGLS) reduced its headcount by an additional 60% and paused recruitment efforts for its RG-012 clinical program in Alport syndrome to save cash. In May 2017, the company reduced its headcount by...
1:07 PM, Jul 13, 2018  |  BC Week In Review | Clinical News  |  Regulatory

EMA's CHMP recommends CAR Ts, rare disease therapies

EMA's CHMP recommended for approval Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel, the first two CAR T therapies backed by the committee. CHMP also recommended a handful of other Orphan drug candidates, including Cablivi caplicizumab, a key...
1:07 PM, Jul 13, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Nohla adds $11M to series B

Off-the-shelf cell therapy company Nohla Therapeutics Inc. (Seattle, Wash.) raised an additional $11 million on June 11 in the second close of a series B financing, bringing the round’s total to $56 million. New investors...
1:07 PM, Jul 13, 2018  |  BC Week In Review | Company News  |  Other News

Vertex, NHS trade barbs over CF pricing

NHS England and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) failed to resolve a stalemate over Orkambi lumacaftor/ivacaftor at their latest meeting to discuss reimbursement of the cystic fibrosis drug. While the two parties released terse statements July 5...
1:06 PM, Jul 13, 2018  |  BC Week In Review | Company News  |  Deals

FTC approves Takeda's Shire takeover

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it received "unconditional clearance" from the Federal Trade Commission (FTC) regarding its proposed acquisition of Shire plc (LSE:SHP; NASDAQ:SHPG). In May, Takeda struck a deal to acquire Shire for...
1:06 PM, Jul 13, 2018  |  BC Week In Review | Company News  |  Deals

Bain acquires Royal DSM, Sinochem JV

The private equity business of Bain Capital LLC (Boston, Mass.) acquired the DSM Sinochem Pharmaceuticals Ltd. JV of Royal DSM N.V. (Euronext:DSM) and Sinochem Group (Beijing, China). Royal DSM will receive about €250 million ($291...
1:06 PM, Jul 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Istari reports Phase I survival data for glioblastoma candidate

Istari Oncology Inc. (Research Triangle Park, N.C.) reported data from 61 patients with recurrent glioblastoma in a Phase I trial showing that Pvsripo led to a median overall survival (OS) of 12.5 months vs. 11.3...
1:00 PM, Jul 13, 2018  |  BC Week In Review | Company News  |  Deals

Novartis returns rights for Aveo's preclinical cachexia program

Novartis AG (NYSE:NVS; SIX:NOVN) will return to Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) rights for AV-380 and other related growth differentiation factor 15 (GDF15) inhibitor antibodies, according to an SEC filing. Aveo granted Novartis exclusive, worldwide rights to...
12:59 PM, Jul 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Cytokinetics' SMA candidate improves time to muscle fatigue in Phase II

Cytokinetics Inc. (NASDAQ:CYTK) reported data from ambulatory patients with spinal muscular atrophy (SMA) in a Phase II trial showing that reldesemtiv led to dose-dependent increases in time to muscle fatigue from baseline to week eight...
12:59 PM, Jul 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Merck KGaA reports response data for tepotinib in c-MET mutant NSCLC

Merck KGaA (Xetra:MRK) said 500 mg once-daily tepotinib (MSC2167119J) led to a partial response rate of 42.9% and a stable disease rate of 21.4% based on independent assessment in the first 28 patients in the...

Pages